With an issue price of 7,50 Hong Kong dollars, the first exchange rate was 14,20 Hong Kong dollars, about 90 percent higher.
发行价为7.50港元，首次兑换价为14.20港元，约高90％。
With the proceeds from the IPO, EuroEyes plans above all to build clinics in major Chinese cities such as Chengdu and Chongqing, make possible acquisitions of clinics in Europe and strengthen its marketing activities.
借助首次公开募股的收益，德视佳眼科首先计划在成都和重庆等中国主要城市开设新诊所，并加强其市场活动。
"In China, there is a huge need for vision correction. According to a market analysis, almost 90 percent of young people are severely nearsighted. We expect 655 million people in 2023. Presbyopia, which is corrected with a trifocal lens, also plays an important role," says Dr. Jrn S. Jrgensen, founder, chairman and CEO of EuroEyes.
“在中国，人们对视力矫正有很大的需求。根据市场分析，将近90％的年轻人是近视眼。我们预计2023年将有6.55亿人。随着中国人口的日益老龄化，用三焦点晶体矫正中老年人的老花眼也将扮演重要的角色来帮助到中国人民”，德视佳眼科创始人，董事长兼首席执行官约根森博士说道。
The Group has established itself as a high-end provider of surgical vision correction in China. "Our unique selling points include the excellent reputation of German ophthalmology, the large number of operations performed, the early use of modern technologies, the quality and comfort of services, customer satisfaction and the outstanding location of the clinics in the major cities," says Dr. Jrgensen.
德视佳国际眼科有限公司(EuroEyes)是提供视力矫正的主流眼科集团之一，已于10月15日成功完成了其股票在香港联合交易所有限公司(“香港联交所”)主板的上市。全球发售所得款项总额为5.95亿港元(包括超额配股权)。
With an issue price of 7,50 Hong Kong dollars, the first exchange rate was 14,20 Hong Kong dollars, about 90 percent higher.
发行价为7.50港元，首次兑换价为14.20港元，约高90％。
With the proceeds from the IPO, EuroEyes plans above all to build clinics in major Chinese cities such as Chengdu and Chongqing, make possible acquisitions of clinics in Europe and strengthen its marketing activities.
借助首次公开募股的收益，德视佳眼科首先计划在成都和重庆等中国主要城市开设新诊所，并加强其市场活动。
"In China, there is a huge need for vision correction. According to a market analysis, almost 90 percent of young people are severely nearsighted. We expect 655 million people in 2023. Presbyopia, which is corrected with a trifocal lens, also plays an important role," says Dr. Jrn S. Jrgensen, founder, chairman and CEO of EuroEyes.
“在中国，人们对视力矫正有很大的需求。根据市场分析，将近90％的年轻人是近视眼。我们预计2023年将有6.55亿人。随着中国人口的日益老龄化，用三焦点晶体矫正中老年人的老花眼也将扮演重要的角色来帮助到中国人民”，德视佳眼科创始人，董事长兼首席执行官约根森博士说道。
The Group has established itself as a high-end provider of surgical vision correction in China. "Our unique selling points include the excellent reputation of German ophthalmology, the large number of operations performed, the early use of modern technologies, the quality and comfort of services, customer satisfaction and the outstanding location of the clinics in the major cities," says Dr. Jrgensen.
德视佳眼科集团已经成为中国视力矫正的高端集团。“我们独特的特点包括德国眼科手术的卓越声誉、大量的手术量、最早使用的现代眼科技术、服务的质量和舒适性、客户满意度以及主要城市诊所的优越地理位置。”约根森博士介绍道。
"We have chosen Hong Kong as our stock exchange location because our future growth is mainly in China and we can finance our expansion from the IPO," says Dr. Markus Braun, CFO of EuroEyes.
德视佳EuroEyes的首席财务官Markus Braun博士说：“我们之所以选择中国香港作为我们的证券交易所在地，是因为我们的未来增长主要集中在中国，我们可以通过IPO筹集资金。”
In the initial public offering, 79,334,000 offer shares were issued by EuroEyes, of which 71,400,000 offer shares were for its international private placement to professional investors and the remaining 7,934,000 shares were for its Hong Kong public offering. Trading of the EuroEyes share
在首次公开募股中，德视佳EuroEyes发行了79,334,000股的发行股份。其中71,400,000股发行是针对专业投资者的国际私募发行，其余7,934,000股则是其在香港的公开发行。德视佳EuroEyes的股份于2019年10月15日开始在联交所买卖。香港公开发售于2019年9月30日开始，并于2019年10月8日完成。报价和最终分配于2019年10月14日宣布。
BOCI Asia Limited acted as global coordinator for the listing. BOCI Asia Limited, China Securities (International) Corporate Finance Company Limited and Fosun Hani Securities Limited acted jointly as bookrunners and lead managers. Eversheds Sutherland was the Hong Kong and German legal adviser to EuroEyes in its listing.
中银国际亚洲有限公司担任上市的全球协调人。中银国际亚洲有限公司，中国证券(国际)企业融资有限公司和复星证券有限公司共同担任账簿管理人和牵头经办人。Eversheds Sutherland是德视佳EuroEyes上市的中国香港和德国法律顾问。
EuroEyes International Eye Clinic Limited is a Cayman Islands incorporated company with significant business in Denmark, Germany and China. In terms of sales, the company ranks first in the market for modern refractive laser and lens surgery (excluding PRK and LASEK) in Germany and second in Denmark. The Group was the first foreign provider of surgical vision correction in the People's Republic of China (besides those from Hong Kong, Macau and Taiwan). EuroEyes has a total of 15 locations in Germany, including its headquarters in Hamburg, 6 locations in China, including Shanghai and Beijing, and a further 5 locations in Denmark.
德视佳国际眼科集团是一家在开曼群岛注册成立的公司。在丹麦，德国和中国拥有重要业务。就销售而言，德视佳眼科在现代屈光激光和晶状体手术(不包括PRK和LASEK)市场上在德国排名第一，在丹麦排名第二。该集团是中华人民共和国(除中国香港，中国澳门和中国台湾地区)首家外国眼科手术视力矫正的德国集团。德视佳眼科EuroEyes在德国共有15个诊所，包括其在德国汉堡的总部；在中国的6个诊所，包括上海、北京、广州、深圳和杭州；以及在丹麦的5个诊所。
Legal Notice
This information does not constitute a public offering of shares in Germany or Denmark or within any other country of the European Monetary Area ("EEA") or outside Hong Kong.
法律声明
该信息不在德国、丹麦或欧洲货币区(“EEA”)的任何其他国家或中国香港以外的地区公开发行股票。
